Evidence map›Paper›PMID 28402724›Full record

ArticleVirulence2017

Carbapenem-resistant Enterobacteriaceae: What we know and what we need to know.

David van Duin

Abstract readEditorial
In one paragraph

Article in Virulence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Carbapenem-resistant Enterobacterales in solid organ transplant recipients.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Genomic Insights Into the Mechanism of Carbapenem Resistance Dissemination in Enterobacterales From a Tertiary Public Heath Setting in South Asia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  9. Review
  10. Resistance to beta-lactams in Gram-negative bacilli: relevance and potential therapeutic alternatives.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

David van Duina Division of Infectious Diseases , University of North Carolina , Chapel Hill , NC , USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
TRAINING IN THE PATHOGENESIS OF INFECTIOUS DISEASEST32AI007517 · NIAID · YALE UNIVERSITY · PI Jaimie Meyer, Albert C Shaw · 1997 to 2026
$6.1M
Molecular Epidemiology of Carbapenem-Resistant Klebsiella pneumoniaeR21AI114508 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., VAN DUIN, DAVID · 2015 to 2016
$445k
NCATS NIH HHS UL1 TR001863NIAID NIH HHS R21 AI114508NIAID NIH HHS T32 AI007517
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Bacterial AgentsCarbapenem-Resistant EnterobacteriaceaeEnterobacteriaceae InfectionsHumansAnti-Bacterial Agentsantibioticcarbapenemasescarbapenem-resistant Enterobacteriaceaeinfectionmultidrug resistance

Identifiers

PMID28402724
PMCPMC5477690

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.